Viking Global Investors
Viking Global Investors is a long/short equity hedge fund. The fund employs a bottom-up fundamental stock-picking strategy for its investments in equities in the U.S. and Europe. It focuses on the financial, telecommunication, media, technology, and consumer sectors. Viking Global Investors is based in New York and was founded in October, 1999 by Andreas Halvorsen, David Ott, and Brian Olson.
Messers. Halvorsen, Ott, and Olson worked together at Tiger Management Corp. All three left Tiger in early 1999.
View Older Stories View More Recent Stories
-
Form SC 13G/A VALVOLINE INC Filed by: VIKING GLOBAL INVESTORS LP
-
Form SC 13G/A Viking Therapeutics, Filed by: VIKING GLOBAL INVESTORS LP
-
Form SC 13G/A NewAmsterdam Pharma Co Filed by: VIKING GLOBAL INVESTORS LP
-
Form SC 13G/A Five9, Inc. Filed by: VIKING GLOBAL INVESTORS LP
-
Form SC 13G/A Verastem, Inc. Filed by: VIKING GLOBAL INVESTORS LP
-
Form SC 13G/A Inhibrx, Inc. Filed by: VIKING GLOBAL INVESTORS LP
-
Areteia Therapeutics Announces Additional $75MM in Series A Financing for Oral Dexpramipexole in Eosinophilic Asthma
-
Neurona Therapeutics Raises $120M to Advance Groundbreaking Pipeline of Regenerative Cell Therapy Candidates for Chronic Neurological Disorders
-
Form SC 13D/A Cazoo Group Ltd Filed by: VIKING GLOBAL INVESTORS LP
-
Form SC 13G Oric Pharmaceuticals, Filed by: VIKING GLOBAL INVESTORS LP
-
Ayana Bio and Wooree Green Science Partner to Develop Plant-Cell Derived Saffron for Health & Wellness Products
-
ORIC Pharmaceuticals (ORIC) Prices 12.5M Share Offering at $10/sh
-
ORIC Pharmaceuticals Announces $125 Million Private Placement Financing
-
Valsoft Corporation Raises Funding to Accelerate Growth in Vertical Market Software
-
Form SC 13G STANDARD BIOTOOLS INC. Filed by: VIKING GLOBAL INVESTORS LP
-
Form SC 13G/A 4D Molecular Therapeutic Filed by: VIKING GLOBAL INVESTORS LP
-
Form SC 13G/A 4D Molecular Therapeutic Filed by: VIKING GLOBAL INVESTORS LP
-
Form 4 4D Molecular Therapeutic For: Jan 04 Filed by: Viking Global Opportunities GP LLC
-
HI-Bio Announces $95 Million Series B Financing to Advance Targeted Therapies for Immune-Mediated Diseases
-
Form 144 APi Group Corp Filed by: VIKING GLOBAL INVESTORS LP
-
Lightmatter Accelerates Growth and Expands Photonic Chip Deployments With $155M in New Funding; Now Valued at $1.2B
-
Ayana Bio Welcomes Industry Veteran Jim Hamilton to its Board of Directors
-
Madryn Asset Management, a Top Shareholder of SomaLogic, Issues Letter Regarding Opposition to the Company’s Proposed Merger with Standard BioTools
-
Battelle, Revive Environmental to Demonstrate PFAS Technology in Department of Defense Project
-
Form SC 13D/A Cazoo Group Ltd Filed by: VIKING GLOBAL INVESTORS LP
-
Alveolus Bio Enters Into Strategic Collaboration with BiomEdit
-
Form SC 13D/A STANDARD BIOTOOLS INC. Filed by: VIKING GLOBAL INVESTORS LP
-
Form SC 13D/A Cazoo Group Ltd Filed by: VIKING GLOBAL INVESTORS LP
-
Form SC 13D/A BridgeBio Pharma, Inc. Filed by: VIKING GLOBAL INVESTORS LP
-
Form 13F-HR VIKING GLOBAL INVESTORS For: Sep 30
-
Form SC 13D/A Cazoo Group Ltd Filed by: VIKING GLOBAL INVESTORS LP
-
Form SC 13G Viking Therapeutics, Filed by: VIKING GLOBAL INVESTORS LP
-
Pearl Health Releases Annual Report and Survey Findings on the State of Primary Care
-
Triveni Bio Launches with $92 Million Series A Financing to Advance Genetics-Informed Precision Medicines for the Treatment of Immunological and Inflammatory (I&I) Disorders
-
DermBiont Announces First Close of $35.2 Million in a Series B Financing to Advance First-in-Class Targeted Topical Dermatological Therapeutics
-
Ayana Bio Launches Plant Cell Advantage™ Portfolio with Three New Health and Wellness Ingredients
-
Form SC 13D STANDARD BIOTOOLS INC. Filed by: VIKING GLOBAL INVESTORS LP
-
Survey data reveals two-thirds of American adults would eat more and pay more for ultra-processed foods that include more nutritious ingredients
-
Form SC 13G Five9, Inc. Filed by: VIKING GLOBAL INVESTORS LP
-
Form D/A Viking Global Opportunit
-
Form D/A Viking Global Equities
-
Form D/A Viking Global Opportunit
-
Form D/A Viking Global Equities
-
Form D/A Viking Global Equities
-
AI startup AlphaSense valued at $2.5 billion after latest funding round
-
AlphaSense Grows to $2.5 Billion Valuation, Securing $150 Million in Series E Funding Led by BOND
-
Battelle Ranked Fifth on Fortune’s 2023 Change the World List for Its PFAS Annihilator® Technology
-
Mythic Therapeutics Receives FDA Fast Track Designation for MYTX-011 for Patients with Non-Small Cell Lung Cancer (NSCLC) with cMET Overexpression
-
Form SC 13D/A Cazoo Group Ltd Filed by: VIKING GLOBAL INVESTORS LP
-
Form SC 13G RayzeBio, Inc. Filed by: VIKING GLOBAL INVESTORS LP

